Tarek A. Wrshana1, Yousry A. Dowidar1, Bahgat A. El-Fiky2, Ali M. El-Rify1, Walaa A. El-Sayed3, Basem M. Ahmed4*
...preliminary step in vNDV immunotherapy where MSCs media could be used for the treatment of vNDV in infected flocks.
Keywords | Newcastle Disease Virus (NDV), mesenchymal stem cells (MSCs), IFN-γ, IL-2, IL-6, IL-12.
...
Qi Jiayi1, Huang XuMiao2, Lin Wei3, Ao YaHui3, Zhao Wenting2* and Cao Chunhao3*
...prognosis prediction and immunotherapy of SKCM....
Aliya Irshad Sani1, Shumaila Usman2*, Zile Rubab1, Sufyan Ahmed3, Sana Iqbal3 and Zehra Ahmed4
...ext-align: justify;">The immunotherapy has emerged as a treatment modality to treat recurrent and advanced tumors. Many immune markers are being evaluated in Oral squamous cell carcinoma (OSCC) including costimulatory molecules OX40 (Tumor necrosis factor receptor superfamily, member 4, TNFSRF4) and OX40L (tumor necrosis factor superfamily, member 4; TNFSF4). They function to potentiate T cells function to accentuate anti-tumor activity. The results of OX40 an...
Qurrat ul Ain Shafique1, Sana Batool2, Hanfa Ashfaq2, Asima Tayyab2, Roquyya Gul3 and Mahjabeen Saleem1*
...proved by FDA for cancer immunotherapy particularly kidney and skin cancer. Interleukin-2 (IL-2) is a 4-helix-bundle type I cytokine possessing a cytokine receptor chain essential for the immune response. The current study presents a vector/host combination (pET28a(+)/IL-2) and optimization of expression in LB,TB and M9 media with varying concentrations of inducers (IPTG and lactose) and post induction time. Maximum expression of IL-2 was achieved in LB with 0...
